Chiesi chipped in as the drug discovery platform developer closed a series B round that will fund its expansion into the agrochemical industry.
Canada-based drug development technology provider Cyclica completed a C$23m ($17m) series B round yesterday that included pharmaceutical company Chiesi Farmaceutici.
Venture capital firm Drive Capital led the round, which also featured investment firm GreenSky Capital and undisclosed members of the company’s management team.
Cyclica has created a drug discover platform that screens proteins expressed by cells (that are known as the proteome) and utilises technology that predicts molecular properties. The cash will support enhancement of its technology as it looks…
